[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Andrew J. Murphy net worth and biography

Andrew Murphy Biography and Net Worth

EVP of Regeneron Pharmaceuticals

Andrew Murphy, PhD, joined Regeneron in 1999 as Director of Genomics and Bioinformatics and is now Executive Vice President of Research. In his time at the company, he has led the Gene Discovery and Bioinformatics and Target Discovery groups. Dr. Murphy is a co-inventor of several of Regeneron's key technologies, VelociGene® and VelocImmune®, and continues to lead several Technology Centers and Therapeutic Focus Areas. Prior to joining Regeneron, Dr. Murphy worked for seven years at Cadus Pharmaceuticals. He received his BS in Molecular Biology at the University of Wisconsin, and his PhD in Human Genetics from Columbia University, College of Physicians and Surgeons.

What is Andrew J. Murphy's net worth?: The estimated net worth of Andrew J. Murphy is at least $35.91 million as of March 14th, 2024. Dr. Murphy owns 48,306 shares of Regeneron Pharmaceuticals stock worth more than $35,908,265 as of November 21st. This net worth estimate does not reflect any other assets that Dr. Murphy may own. Additionally, Dr. Murphy receives an annual salary of $1,680,000.00 as EVP at Regeneron Pharmaceuticals. Learn More about Andrew J. Murphy's net worth.
How old is Andrew J. Murphy?: Dr. Murphy is currently 65 years old. There are 4 older executives and no younger executives at Regeneron Pharmaceuticals. The oldest executive at Regeneron Pharmaceuticals is Dr. Leonard S. Schleifer M.D., Ph.D., Co-Founder, President, CEO & Co-Chairman, who is 71 years old. Learn More on Andrew J. Murphy's age.
What is Andrew J. Murphy's salary?: As the EVP of Regeneron Pharmaceuticals, Inc., Dr. Murphy earns $1,680,000.00 per year. There are 4 executives that earn more than Dr. Murphy. The highest earning executive at Regeneron Pharmaceuticals is Dr. Leonard S. Schleifer M.D., Ph.D., Co-Founder, President, CEO & Co-Chairman, who commands a salary of $8,180,000.00 per year. Learn More on Andrew J. Murphy's salary.
How do I contact Andrew J. Murphy?: The corporate mailing address for Dr. Murphy and other Regeneron Pharmaceuticals executives is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. Regeneron Pharmaceuticals can also be reached via phone at (914) 847-7000 and via email at [email protected]. Learn More on Andrew J. Murphy's contact information.
Has Andrew J. Murphy been buying or selling shares of Regeneron Pharmaceuticals?: Andrew J. Murphy has not been actively trading shares of Regeneron Pharmaceuticals over the course of the past ninety days. Most recently, Andrew J. Murphy sold 5,783 shares of the business's stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a transaction totalling $5,531,266.01. Following the completion of the sale, the executive vice president now directly owns 48,306 shares of the company's stock, valued at $46,203,239.82. Learn More on Andrew J. Murphy's trading history.
Who are Regeneron Pharmaceuticals' active insiders?: Regeneron Pharmaceuticals' insider roster includes Bonnie Bassler (Director), Michael Brown (Director), N. Coles (Director), Christopher Fenimore (VP), Joseph Goldstein (Director), Robert Landry (CFO), Joseph Larosa (EVP), Marion Mccourt (EVP), Andrew Murphy (EVP), Christine Poon (Director), Arthur Ryan (Director), Leonard Schleifer (CEO), George Sing (Director), Neil Stahl (EVP), Marc Tessier-Lavigne (Director), P. Vagelos (Director), Daniel Van Plew (EVP), George Yancopoulos (Insider), and Huda Zoghbi (Director). Learn More on Regeneron Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Regeneron Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 28 times. They sold a total of 108,095 shares worth more than $105,638,222.64. The most recent insider tranaction occured on August, 28th when CFO Christopher R Fenimore sold 5,680 shares worth more than $6,846,274.40. Insiders at Regeneron Pharmaceuticals own 7.5% of the company. Learn More about insider trades at Regeneron Pharmaceuticals.
Information on this page was last updated on 8/28/2024.

Andrew J. Murphy Insider Trading History at Regeneron Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/14/2024	Sell	5,783	$956.47	$5,531,266.01	48,306
12/10/2021	Sell	7,122	$666.27	$4,745,174.94
11/16/2021	Sell	7,167	$647.17	$4,638,267.39
7/14/2020	Sell	2,380	$633.48	$1,507,682.40	44,067
1/27/2020	Sell	8,000	$340.91	$2,727,280.00	57,751

Andrew J. Murphy Buying and Selling Activity at Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Today's Range

Now: $743.35

$736.01

$750.69

50 Day Range

MA: $961.76

$743.35

$1,164.46

2 Week Range

Now: $743.35

$736.01

$1,211.20

Volume

654,394 shs

Average Volume

860,893 shs

Market Capitalization

$81.69 billion

P/E Ratio

18.40

Dividend Yield

N/A

Beta

0.15

[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

From Crypto Swap Profits | Ad

Andrew Murphy Biography and Net Worth

What is Andrew J. Murphy's net worth?

How old is Andrew J. Murphy?

What is Andrew J. Murphy's salary?

How do I contact Andrew J. Murphy?

Has Andrew J. Murphy been buying or selling shares of Regeneron Pharmaceuticals?

Who are Regeneron Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Regeneron Pharmaceuticals?